STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more

Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again.

And to celebrate, we are brewing still more cups of stimulation and inviting you to join us. Our choice today is Jack Daniel’s.

Yes, this is a real thing. And remember, a prescription is not required.

So no need to mess with rebates, coupons, or TrumpRx. Meanwhile, here are a few items of interest.

Hope you have a smashing day and conquer the world. And of course, do stay in touch.

We appreciate feedback, criticism and tips. … Sanofi asked the U.S.

Food and Drug Administration to pull its type 1 diabetes drug, teplizumab, out of FDA Commissioner Marty Makary’s new speedy review program , STAT reports. The move comes after acting Center for Drug Evaluation and Research Director Tracy Beth Høeg disagreed with a staff decision to approve the drug.

The agency missed its April 21 goal date to deliver a decision to Sanofi. Such decisions are typically made by career scientists.